Mandate

Vinge advises Surgical Science in conjunction with a directed new issue of shares valued at SEK 2.7 billion

Surgical Science Sweden AB, listed on Nasdaq First North Growth Market, has performed a directed new issue of shares valued at approximately SEK 2.7 billion at a subscription price of SEK 210.

The subscription price was established through a so-called accelerated book building procedure arranged by Pareto Securities. The net proceeds from the directed issue of shares will primarily be used to finance the acquisition of Simbionix USA Corp which was made public on the same day as the directed new issue of shares. 

Vinge’s team consisted of Anders Strid, Edin Agic (project manager) and Adrian Filipovic.

 

 

Related

Vinge has advised EQT AB in connection with the refinancing of EQT’s EUR 1,500,000,000 sustainability-linked revolving credit facility

The sustainability-linked credit facility has a tenor of 5 years with two 1-year extension options.
July 23, 2024

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.
July 19, 2024

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024